Lyra TherapeuticsLYRA
LYRA
About: Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Employees: 30
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
75% more call options, than puts
Call options by funds: $7K | Put options by funds: $4K
6% more funds holding
Funds holding: 54 [Q4 2024] → 57 (+3) [Q1 2025]
2.22% less ownership
Funds ownership: 41.07% [Q4 2024] → 38.85% (-2.22%) [Q1 2025]
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
42% less capital invested
Capital invested by funds: $5.55M [Q4 2024] → $3.23M (-$2.32M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$16
85%
upside
Avg. target
$16
85%
upside
High target
$16
85%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Matthew Caufield | 85%upside $16 | Neutral Maintained | 10 Jun 2025 |
Financial journalist opinion
Based on 3 articles about LYRA published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants
Neutral
Seeking Alpha
3 weeks ago
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, strong supporting data, and a good explanation for the ENLIGHTEN-1 failure, I believe the market is underestimating the potential for NDA submission without the need of another phase 3. Assuming positive FDA feedback, I expect considerable upside, allowing LYRA to raise much needed cash from a strong position.
Positive
Zacks Investment Research
4 weeks ago
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
1 month ago
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
Positive
Finbold
1 month ago
This penny stock just spiked 550% in a day; Time to buy?
Lyra Therapeutics (NASDAQ: LYRA) ‘s shares surged 550% in pre-market trading on Monday following a breakthrough in its drug trials.
Positive
Benzinga
1 month ago
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?
Lyra Therapeutics, Inc. LYRA released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with Chronic Rhinosinusitis (CRS).
Neutral
GlobeNewsWire
1 month ago
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210 in adult patients with CRS. The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (-1.13; p=0.0078) in patients without nasal polyps.
Neutral
GlobeNewsWire
2 months ago
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the Company's lead product candidate for CRS, at the annual Combined Otolaryngology Spring Meetings (COSM 2025) being held May 14-18 in New Orleans.
Negative
Zacks Investment Research
2 months ago
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – – Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 –
Charts implemented using Lightweight Charts™